SCHEMBL7658196

SCHEMBL7658196

CC(C)(C)n1nc(-c2ccccc2)[nH]c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY6 Q15077 3/20 0.45
BTK Q06187 1/20 0.42
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ADORA2B P29275 3/20 0.41
ADORA2A P29274 2/20 0.41
ADORA3 P0DMS8 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
ADORA1 P30542 1/20 0.41
BLM P54132 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ATM Q13315 1/20 0.41
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265647 0.77 ATM (0.65) BTKPOLBL3MBTL1ADORA2BADORA2A
SCHEMBL15759808 0.73 BTK (0.46) BTKHPGDSMN1; SMN2POLBL3MBTL1
SCHEMBL13068443 0.73 BTK (0.46) BTKHPGDSMN1; SMN2POLBL3MBTL1
SCHEMBL12400717 0.72 ADORA2B (0.48) BTKHPGDPOLBL3MBTL1ADORA2B
SCHEMBL7650664 0.71 ADORA3 (0.44) BTKHPGDSMN1; SMN2POLBL3MBTL1
SCHEMBL404497 0.71 CALCRL (0.45) POLB
SCHEMBL7652937 0.69 TNKS (0.47) HPGDSMN1; SMN2POLBL3MBTL1ADORA3
SCHEMBL7652867 0.69 ALDH1A1 (0.48) BTKPOLBL3MBTL1ADORA2BADORA2A
SCHEMBL12372714 0.68 ERCC1 (0.46) SMN1; SMN2ADORA2BADORA2AADORA3KDM4E
SCHEMBL7654102 0.68 ADORA2B (0.41) BTKHPGDPOLBL3MBTL1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994325-B2 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide MERCK SHARP & DOHME CORP. (US) 2011-08-09 US disclosed
US-20080261972-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-10-23 US disclosed
US-6492407-B2 NEUROPROTECTIVE ACTIVITY BOEHRINGER IMGELHEIM PHARMA KG (DE) 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261972-A1 Cgrp Receptor Antagonists BDKRB1, CALCRL, NPY1R P2RY6 168/4885BTK 2977/4885HPGD 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.